Comparison of traditional cardiovascular risk factors and clinical characteristics between PsA patients with and those without subclinical LV dysfunction.
| Characteristics | PsA Patients, n = 94 | Subclinical LV Dysfunction | p | |
|---|---|---|---|---|
| No, n = 33 | Yes, n = 61 | |||
| Age, yrs | 48.2 ± 12.2 | 40.9 ± 10.7 | 52.1 ± 11.2 | < 0.001 |
| Hypertension, n (%) | 40 (42.6) | 6 (18.2) | 34 (55.7) | < 0.001 |
| Hyperlipidemia, n (%) | 12 (12.8) | 1 (3.0) | 11 (18.0) | 0.037 |
| Age at psoriasis diagnosis, yrs | 35.8 ± 14.3 | 30.4 ± 13.2 | 38.5 ± 14.2 | 0.012 |
| Age at PsA diagnosis, yrs | 39.4 ± 12.1 | 34.0 ± 11.0 | 42.6 ± 11.6 | 0.001 |
| Age at PsA diagnosis > 40 yrs, n (%) | 48 (51.1) | 10 (30.3) | 38 (63.3) | 0.002 |
| Psoriasis duration, yrs, median (IQR) | 12.5 (5.0–16.7) | 11.0 (4.1–15.7) | 13.2 (6.5–17.1) | 0.181 |
| PsA duration, yrs, median (IQR) | 7.9 (2.5–12.5) | 5.3 (1.2–11.6) | 9.4 (4.3–13.0) | 0.046 |
| PsA duration > 5 yrs, n (%) | 45 (47.9) | 11 (33.3) | 34 (55.7) | 0.038 |
| Disease pattern | ||||
| Peripheral, n (%) | 78 (83.0) | 28 (84.8) | 50 (82.0) | 0.723 |
| Spondylarthritis, n (%) | 16 (17.0) | 5 (15.2) | 11 (18.0) | |
| DAS28, n (%) | 3.7 ± 1.5 | 3.7 (1.4) | 3.7 (1.5) | 0.946 |
| Inactive (DAS28 ≤ 3.2) | 36 (38.3) | 13 (39.4) | 23 (37.7) | 0.986 |
| Moderate (3.2 < DAS28 ≤ 5.1) | 35 (37.2) | 12 (36.4) | 23 (37.7) | |
| Very active (DAS28 > 5.1) | 23 (24.5) | 8 (24.2) | 15 (24.6) | |
| Skin abnormal, n (%) | ||||
| Psoriasis vulgaris | 44 (46.8) | 19 (57.6) | 25 (41.0) | 0.124 |
| Flexural psoriasis | 44 (46.8) | 15 (45.5) | 29 (47.5) | 0.847 |
| Guttate | 40 (42.6) | 12 (34.6) | 28 (45.9) | 0.372 |
| Erythrodema | 47 (50.0) | 13 (39.4) | 34 (55.7) | 0.130 |
| Nail lesions, n (%) | ||||
| Pits | 42 (44.7) | 12 (36.4) | 30 (49.2) | 0.233 |
| Onycholysis | 35 (37.2) | 12 (36.4) | 23 (65.7) | 0.898 |
| Ridges | 39 (41.5) | 11 (33.3) | 28 (45.9) | 0.238 |
| PASI, median (IQR) | 2.4 (1.0–8.5) | 2.1 (0.6–12.0) | 2.6 (1.0–8.1) | 0.955 |
| HAQ, median (IQR) | 0.4 (0.1–0.9) | 0.4 (0–0.6) | 0.4 (0.1–1.0) | 0.498 |
| Apo A-1, mg/dl | 143.7 ± 33.5 | 135.6 ± 33.9 | 146.5 ± 33.3 | 0.284 |
| Apo B, mg/dl | 82.4 ± 17.3 | 81.0 ± 17.8 | 83.0 ± 17.3 | 0.704 |
| hs-CRP, median (IQR), mg/l | 4.7 (1.6–14.3) | 5.6 (1.5–16.0) | 4.3 (1.7–11.5) | 0.598 |
| Serum creatinine, μmol/l | 74.8 ± 16.1 | 68.9 ± 16.8 | 77.0 ± 15.4 | 0.048 |
| Current NSAID, n (%) | 56 (59.6) | 22 (66.7) | 34 (55.7) | 0.223 |
| Current DMARD, n (%) | 50 (53.2) | 15 (44.5) | 35 (57.4) | 0.269 |
| Corticosteroid ever, n (%) | 8 (8.5) | 4 (12.1) | 4 (6.6) | 0.238 |
| Current antihypertensive therapy, n (%) | 21 (22.3) | 2 (6.1) | 19 (31.1) | 0.005 |
| Calcium-channel blocker | 10 (10.6) | 0 | 10 (16.4) | 0.014 |
| ACEI/ARB | 5 (5.3) | 1 (3.0) | 4 (6.6) | 0.476 |
| ß-blocker | 11 (11.7) | 1 (3.0) | 10 (16.4) | 0.054 |
| Diuretics | 2 (2.1) | 0 | 2 (3.3) | 0.293 |
IQR: interquartile range; DAS28: Disease Activity Score in 28 joints; PASI: Psoriasis Area and Severity Index; Apo A-1: apolipoprotein A 1; Apo B: apolipoprotein B; hs-CRP: high-sensitivity C-reactive protein; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; HAQ: Health Assessment Questionnaire.